Secretome Therapeutics is a clinical-stage cell therapy company that develops therapies for rare cardiac diseases.
Secretome Therapeutics has raised $30.0M in total funding. The most recent round was Series A. The last funding was announced in May 2026.
Secretome Therapeutics's investors include RA Capital Management, TEDCO, University System of Maryland Momentum Fund, Parent Project Muscular Dystrophy, HEST.
Secretome Therapeutics is headquartered in Dallas, United States.
Secretome Therapeutics is a clinical-stage cell therapy company that develops therapies for rare cardiac diseases.
Secretome Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Secretome Therapeutics — Funding & Investors." VCBacked, May 27, 2026, https://www.vcbacked.co/company/secretome-therapeutics. Accessed July 19, 2026.
VCBacked. (2026). Secretome Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/secretome-therapeutics
{{cite web |title=Secretome Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/secretome-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated